vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and BRC Group Holdings, Inc. (RILY). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $188.3M, roughly 1.5× BRC Group Holdings, Inc.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 47.9%, a 48.4% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs -21.9%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs -15.4%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
ACAD vs RILY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $188.3M |
| Net Profit | $273.6M | $90.3M |
| Gross Margin | 90.8% | 79.5% |
| Operating Margin | 6.1% | 32.3% |
| Net Margin | 96.3% | 47.9% |
| Revenue YoY | 9.4% | -21.9% |
| Net Profit YoY | 90.3% | 1710.8% |
| EPS (diluted) | $1.61 | $2.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $188.3M | ||
| Q3 25 | $278.6M | $215.3M | ||
| Q2 25 | $264.6M | $188.2M | ||
| Q1 25 | $244.3M | $197.2M | ||
| Q4 24 | $259.6M | $241.0M | ||
| Q3 24 | $250.4M | $225.5M | ||
| Q2 24 | $242.0M | $256.0M | ||
| Q1 24 | $205.8M | $263.4M |
| Q4 25 | $273.6M | $90.3M | ||
| Q3 25 | $71.8M | $91.1M | ||
| Q2 25 | $26.7M | $139.5M | ||
| Q1 25 | $19.0M | $-10.0M | ||
| Q4 24 | $143.7M | $-5.6M | ||
| Q3 24 | $32.8M | $-284.4M | ||
| Q2 24 | $33.4M | $-433.6M | ||
| Q1 24 | $16.6M | $-49.2M |
| Q4 25 | 90.8% | 79.5% | ||
| Q3 25 | 92.2% | 83.7% | ||
| Q2 25 | 92.2% | 81.3% | ||
| Q1 25 | 91.7% | 81.4% | ||
| Q4 24 | 91.6% | 79.8% | ||
| Q3 24 | 92.5% | 82.1% | ||
| Q2 24 | 92.5% | 84.5% | ||
| Q1 24 | 88.8% | 85.3% |
| Q4 25 | 6.1% | 32.3% | ||
| Q3 25 | 12.8% | 30.4% | ||
| Q2 25 | 12.2% | 5.7% | ||
| Q1 25 | 7.9% | -31.2% | ||
| Q4 24 | 59.1% | -69.2% | ||
| Q3 24 | 12.6% | -36.4% | ||
| Q2 24 | 12.6% | -90.8% | ||
| Q1 24 | 7.4% | -6.1% |
| Q4 25 | 96.3% | 47.9% | ||
| Q3 25 | 25.8% | 42.3% | ||
| Q2 25 | 10.1% | 74.1% | ||
| Q1 25 | 7.8% | -5.1% | ||
| Q4 24 | 55.4% | -2.3% | ||
| Q3 24 | 13.1% | -126.1% | ||
| Q2 24 | 13.8% | -169.4% | ||
| Q1 24 | 8.0% | -18.7% |
| Q4 25 | $1.61 | $2.78 | ||
| Q3 25 | $0.42 | $2.91 | ||
| Q2 25 | $0.16 | $4.50 | ||
| Q1 25 | $0.11 | $-0.39 | ||
| Q4 24 | $0.86 | $-0.01 | ||
| Q3 24 | $0.20 | $-9.39 | ||
| Q2 24 | $0.20 | $-14.35 | ||
| Q1 24 | $0.10 | $-1.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $226.6M |
| Total DebtLower is stronger | — | $1.4B |
| Stockholders' EquityBook value | $1.2B | $-171.5M |
| Total Assets | $1.6B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $226.6M | ||
| Q3 25 | $258.0M | $184.2M | ||
| Q2 25 | $253.6M | $267.4M | ||
| Q1 25 | $217.7M | $138.3M | ||
| Q4 24 | $319.6M | $146.9M | ||
| Q3 24 | $155.1M | $159.2M | ||
| Q2 24 | $177.1M | $236.9M | ||
| Q1 24 | $204.7M | $190.7M |
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $-171.5M | ||
| Q3 25 | $917.3M | $-260.5M | ||
| Q2 25 | $822.4M | $-351.7M | ||
| Q1 25 | $765.2M | $-496.8M | ||
| Q4 24 | $732.8M | $-488.2M | ||
| Q3 24 | $577.2M | $-497.6M | ||
| Q2 24 | $516.7M | $-218.3M | ||
| Q1 24 | $464.0M | $228.4M |
| Q4 25 | $1.6B | $1.7B | ||
| Q3 25 | $1.3B | $1.7B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.1B | $1.5B | ||
| Q4 24 | $1.2B | $1.8B | ||
| Q3 24 | $976.9M | $2.2B | ||
| Q2 24 | $914.1M | $3.2B | ||
| Q1 24 | $855.1M | $5.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $26.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | 0.29× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $26.2M | ||
| Q3 25 | $74.3M | $-60.6M | ||
| Q2 25 | $64.0M | $-25.6M | ||
| Q1 25 | $20.3M | $184.0K | ||
| Q4 24 | $40.4M | $-2.7M | ||
| Q3 24 | $63.2M | $19.5M | ||
| Q2 24 | $25.0M | $111.5M | ||
| Q1 24 | $29.1M | $135.4M |
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -0.18× | 0.29× | ||
| Q3 25 | 1.03× | -0.66× | ||
| Q2 25 | 2.40× | -0.18× | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
